Previous 10 | Next 10 |
Edesa Biotech (NASDAQ: EDSA ) +218% on launch of COVID-19 study in Canada. More news on: Edesa Biotech, Inc., Brickell Biotech, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...
VTv Therapeutics (NASDAQ: VTVT ) is up 45% premarket on the heels of results from the Phase 2 Simplici-T1 study evaluating TTP399 as an adjunct to insulin therapy in adults with type 1 diabetes. More news on: vTv Therapeutics Inc., Healthcare stocks news, Read m...
As of 5:50 AM, here are the stocks that are up most and down most in early premarket trading. More news on: China HGS Real Estate Inc., vTv Therapeutics Inc., China Natural Resources, Inc., , Stocks on the move, News on ETFs Read more ...
- Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) - HIGH POINT, N.C., June 13, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today made two p...
VTv Therapeutics' (NASDAQ: VTVT ) two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented at the American Diabetes Association’s 80th Scientific Sessions, which is being held virtually, June 12 ...
HIGH POINT, N.C., May 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Associa...
HIGH POINT, N.C., May 22, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-only meeting that will be held via live audio webcast due to the public health and safety ...
Gainers: SIFCO Industries (NYSEMKT: SIF ) +94% . More news on: SIFCO Industries, Inc., Creative Realities, Inc., United Natural Foods, Inc., Stocks on the move, , Read more ...
vTv Therapeutics (NASDAQ: VTVT ): Q1 Non-GAAP EPS of -$0.11 misses by $0.01 ; GAAP EPS of -$0.11. More news on: vTv Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HIGH POINT, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2020, and provided an update on recent clinical achievements. “In spite of the challenges presented by the COVID-19 pande...
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has pla...
2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...